GGrantIndex
Sort

48,018 grants matching immunotherapy

Lymphoma Studies

$681,876
Wyndham H Wilson · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA

Immune Mechanisms in Ocular Graft versus Host Disease

$681,732
Victor L Perez · University Of Miami School Of Medicine · R01 · FY2015 · EY

Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy

$681,634
Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2021 · AI

A Novel Intervention Strategy for Stroke with RTL Therapy

$681,615
Halina Offner · Virogenomics, Inc. · R42 · FY2012 · NS

Conserved Element DNA Vaccine

$681,593
Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer

$681,544
Sanaz Memarzadeh · University Of California Los Angeles · R01 · FY2025 · CA

Cytokine-mediated regulation of immunity and microenvironment in colorectal cancer metastasis

$681,537
Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2025 · CA

Cytokine-mediated regulation of immunity and microenvironment in colorectal cancer metastasis

$681,537
Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2024 · CA

Epigenetic Therapy for Thoracic Malignancies

$681,523
David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA

Cytokines and T Cell Development

$681,506
Scott Durum · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma

$681,501
Mark Yarchoan · Johns Hopkins University · R01 · FY2024 · CA

Immunobiology and immunotherapy of pancreatic cancer

$681,452
Robert H Vonderheide · University Of Pennsylvania · R01 · FY2016 · CA

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs

$681,410
Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · DE

Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma

$681,408
Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2017 · CA

Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy

$681,404
Daniel B Stetson · University Of Washington · R01 · FY2024 · CA

The Impact of a Changing Health Care Delivery System on the Quality of Oncology Care

$681,389
Nancy L Keating · Harvard Medical School · R01 · FY2022 · CA

Innate-adaptive crosstalk in protective and vaccine-induced immunity to TB

$681,243
Jyothi Rengarajan · Emory University · R01 · FY2020 · AI

Metabolic regulation of immunosuppressive myeloid cells in the tumor microenvironment of pancreatic cancer.

$681,198
Yaqing Zhang · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

MATCHMAKERS - Creating and training AI tools for TCR binding prediction and design

$681,176
Michael Birnbaum · Massachusetts Institute Of Technology · OT2 · FY2024 · CA

Clinical Trials Engine to Develop an HIV Cure study to test engineered T cells

$681,125
Christina M Coughlin · University Of Pennsylvania · U19 · FY2023 · AI

Alpha-Emitter Therapy of Osteosarcoma

$681,116
George Sgouros · Johns Hopkins University · R01 · FY2024 · CA

Home-based actigraphy to predict disability progression and enhance clinical trials in multiple sclerosis

$681,094
Ellen M. Mowry · Johns Hopkins University · R01 · FY2022 · NR

Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer

$681,039
Jennifer D Wu · Cancure, Llc · R44 · FY2020 · CA

Developmental Core

$680,925
Elizabeth A Klonoff · San Diego State University · U54 · FY2008 · CA

Selective disruption of histone deacetylase complexes using protein interaction modulators

$680,864
Marc Vidal · Dana-Farber Cancer Inst · R01 · FY2022 · CA